Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023.

ABSTRACT:

Background

Data on the contemporary prevalence of hypertrophic cardiomyopathy (HCM) in the United States are limited, and information on the epidemiology by disease characteristics and patient demographics is lacking.

Objectives

This study aimed to estimate the prevalence and incidence of HCM in the United States from 2016 to 2023 overall and stratified by patient subgroups.

Methods

In this observational study, patient-level administrative claims from 2016 to 2023 were collected from the Symphony Integrated Dataverse. Selected patients were those with ≥1 HCM diagnosis code during the study period. Patients were designated as having nonobstructive HCM (nHCM), obstructive HCM (oHCM), and symptomatic HCM using diagnosis codes.

Results

During the period of 2016-202

SUBMITTER: Butzner M 

PROVIDER: S-EPMC12859511 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature